Impact of Rapid Molecular Panel-Based Testing for Urinary Tract Infections

Examining Clinical and Economic Effects

Urinary tract infections (UTIs) have traditionally been diagnosed with culture-based microbiology tests, which can lack sensitivity and specificity, are prone to contamination, and take 18 to 24 hours to deliver results. Now that diagnostic molecular testing is available, data has been collected about the impact on UTI testing.

Laboratories that have replaced culture-based methods of testing for urinary tract infections with new molecular methods have benefitted from easier testing, shorter time to answer, higher sensitivity and specificity, and less contamination.

In this P.A.C.E.-accredited Fisher Healthcare webinar, Trisha Lauterbach, MSA, and David Baunoch, PhD, will discuss recent data demonstrating the clinical, economic, and laboratory impact of these new tests.

Learning Objectives

This webinar will help you:

• Identify the problems and limitations of detecting infections using culture-based testing
• Describe current clinical trials and medical practice trends in rapid molecular testing for UTIs
• Explain the economic impact and reimbursement trends for molecular testing for UTI detection

Watch on Demand      Download Slides (PDF, 2MB)

This webinar is produced by Whitehat Communications, a provider of continuing education programs in clinical laboratory sciences that has been approved by the ASCLS P.A.C.E.™ Program. One P.A.C.E. credit hour will be provided for this complimentary, basic-level program.

Trisha Lauterbach, MSA, MLS (ASCP), CHT (ASHI)

As the Director of Laboratory Operations at Capstone Healthcare, Trisha Lauterbach applies her expertise in clinical molecular testing to improve patient care and outcomes in diverse healthcare settings and patient populations. She earned her Bachelor of Science in Clinical Laboratory Science from the University of Nebraska Medical Center and her Master of Science in Health Care Administration from the University of South Dakota. She is board of registry certified as a Medical Laboratory Scientist (ASCP) and a Certified Histocompatibility Technologist (ASHI). With over a decade of clinical laboratory experience in a large healthcare system, Lauterbach is passionate about helping to improve the health and wellness of patients and communities through innovative technologies that offer more personalized treatment.

David Baunoch, PhD

Dr. Baunoch is the President and CEO of Pathnostics. He received his PhD in microbiology and molecular genetics from Wayne State University and completed an NIH Postdoctoral Fellowship in breast cancer research at the Michigan Cancer Foundation. Baunoch has more than 25 years of laboratory experience and has produced several dozen papers for peer-reviewed publications. Before founding LabPath, he held a variety of executive management positions with industry-leading companies, including Ventana Medical Systems and US LABS, and was founder and president of Combimatrix Molecular Diagnostics.